Departamento de Medicina Preventiva da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Departamento de Moléstias Infecciosas e Parasitarias da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.
Clinics (Sao Paulo). 2023 Jun 13;78:100233. doi: 10.1016/j.clinsp.2023.100233. eCollection 2023.
To summarize the data on SARS-CoV-2 seroprevalence surveys conducted in Brazil before the introduction of vaccines METHODS: The authors conducted a systematic review and meta-analysis on the seroprevalence of SARS-CoV-2 infection in Brazil. The present review followed the PRISMA guidelines. The authors searched Medline, Embase, and LILACS databases for serologic surveys conducted in the Brazilian population, in the period from 01/10/2019 to 07/11/2021, without language restrictions. The authors included studies that presented data concerning SARS-CoV-2 antibodies seroprevalence in Brazil and had a sample size ≥50 individuals. Considering the expected heterogeneity between studies, all analyses were performed using the random effects model, and heterogeneity was assessed using the I statistic RESULTS: Of 586 publications identified in the initial searches, 54 were included in the review and meta-analysis, which contained the results of 135 surveys, with 336,620 participants. The estimated seroprevalence was 11.0%, ranging from 1.0% to 83.0%, with a substantial heterogeneity (I = 99.55%). In subgroup analyses, the authors observed that the prevalence of SARS-CoV-2 antibodies was 13.0% in blood donors, 9.0% in the population-based surveys, 13% in schoolchildren, and 11.0% in healthcare workers.
Seroprevalence increases over time. Large differences were observed among the regions of the country. It was higher in the Northern region, decreasing towards the South. The present results may contribute to the analysis of the spread of SARS-CoV-2 infection in the Brazilian population before vaccination, one of the factors that may be influencing the clinical presentation of COVID-19 cases related to the new variants, as well as the effectiveness of the vaccination program.
总结在巴西引入疫苗之前进行的 SARS-CoV-2 血清流行率调查的数据。
作者对巴西 SARS-CoV-2 感染血清流行率的血清学调查进行了系统评价和荟萃分析。本综述遵循 PRISMA 指南。作者在 Medline、Embase 和 LILACS 数据库中搜索了 2019 年 10 月 1 日至 2021 年 7 月 11 日期间在巴西人群中进行的血清学调查,无语言限制。作者纳入了报告巴西 SARS-CoV-2 抗体血清流行率且样本量≥50 人的研究。考虑到研究之间存在预期的异质性,所有分析均使用随机效应模型进行,使用 I 统计量评估异质性。
在最初的搜索中,共确定了 586 篇文献,其中 54 篇文献被纳入综述和荟萃分析,其中包含 135 项调查的结果,涉及 336620 名参与者。估计的血清流行率为 11.0%,范围为 1.0%至 83.0%,具有很大的异质性(I=99.55%)。在亚组分析中,作者观察到献血者 SARS-CoV-2 抗体的流行率为 13.0%,基于人群的调查为 9.0%,学童为 13%,医护人员为 11.0%。
血清流行率随时间增加。该国各地区之间存在很大差异。北部地区较高,向南逐渐下降。目前的结果可能有助于分析巴西人群在接种疫苗前 SARS-CoV-2 感染的传播情况,这是影响与新变异相关的 COVID-19 病例临床表现以及疫苗接种计划有效性的因素之一。